ABSTRACT
BACKGROUND: Acute myeloid leukemia (AML) is the most common leukemia in adults. Aim: To Describe our population of patients with AML and report the outcomes of our treatments. MATERIAL AND METHODS: Review of electronic clinical records of 114 patients with AML with a median age of 57 years (59% men). Results: Seventeen percent of patients were classified as low risk, 38% as intermediate risk and 33% as high risk. Seventy-six percent of patients were treated with intensive chemotherapy. Five years overall survival according to cytogenetic risk was 59, 41, and 12% in low, intermediate, and high-risk patients, respectively. The outcomes were better in patients under 60 years. The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively. CONCLUSIONS: Our results are comparable to those reported in developed countries. Improving the survival of patients 60 years and older is our main challenge.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Leukemia, Myelomonocytic, Acute/genetics , Leukemia, Myelomonocytic, Acute/drug therapy , Retrospective Studies , Treatment OutcomeABSTRACT
Background: In our country, transplantation centers differ in the age limit for allogeneic hematopoietic transplantation (ALOHT). In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. Material and Methods: A retrospective analysis of the database of adult hematopoietic transplants in AML patients was performed. Demographic data, disease characteristics, transplant data, survival and relapse times, and mortality were collected. Results: In our program, 1030 transplants were performed in adults and 119 ALOHT were performed in AML patients, between 1990 and 2020. The median age of patients in all periods was 41 years, (range 16-69). The median age was 33 and 45 years, in the periods 1990-2000 and 2000-2020 respectively (p < 0.01). Seventy-eight patients received myeloablative conditioning (median age 44 years) and 41 reduced intensity conditioning (median age 53 years). Five-year overall survival was 44.6% (confidence intervals (CI) 41-48). Non relapse mortality of all periods was 19% (CI 17 - 40%) and relapse rate was 17 % (CI 16-22). No difference in five years overall survival among patients younger than 40, 41 to 50 and over 51 years was observed. Conclusions: Overall Survival, non-relapse mortality and relapse rate were similar in younger and older patients in our program and similar to those previously reported in other centers.
ABSTRACT
Background: Mantle cell lymphoma (MCL) has high relapse and mortality rates. There is a survival benefit when treatment is intensified with cytarabine (AraC), hematopoietic cell transplantation (HCT) and maintenance with rituximab. Aim: To assess the outcomes of patients with MCL treated in a university hospital. Material and Methods: Review of an oncology center database and medical records identifying patients with MCL treated between 2006 and 2017. Death dates were obtained from the death certificate database of the National Identification Service. We analyzed the response rate, overall survival (OS) and progression-free survival (PFS). As a secondary objective, the survival impact of AraC, HCT and maintenance with rituximab, was also analyzed. Results: Information on 20 patients aged 62 ± 11 years, followed for a median of 45 months was retrieved. Eighty-five percent were diagnosed at an advanced stage. The most used first-line regime was R-CHOP in 11 patients, followed by R-HyperCVAD in five. Only 47% achieved complete response. 4-year PFS and OS were of 30 and 77% respectively. Mantle Cell Lymphoma International Prognostic Index (MIPI) significantly predicted PFS and OS. Maintenance with rituximab or HCT was associated with better PFS (48 vs 21 months, p < 0.01). The exposure to AraC or HCT, in refractory or relapsed disease, was associated with an increase in PFS from 9 to 28 months (p = 0,02) and 4-year OS from 40 to 100% (p = 0.05). OS increased even more, from 25 to 100% in those with high-risk MIPI (p = 0.04). Conclusions: The incorporation of AraC, HCT and maintenance with rituximab in the therapeutic backbone of MCL, especially for high-risk cases, was associated with improved survival.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Hematopoietic Stem Cell Transplantation/methods , Lymphoma, Mantle-Cell/surgery , Lymphoma, Mantle-Cell/drug therapy , Cytarabine/therapeutic use , Rituximab/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , Time Factors , Retrospective Studies , Risk Factors , Treatment Outcome , Sex Distribution , Combined Modality Therapy , Age Distribution , Statistics, Nonparametric , Lymphoma, Mantle-Cell/mortality , Kaplan-Meier Estimate , Progression-Free Survival , Neoplasm Recurrence, LocalABSTRACT
Background: The neutrophil/lymphocyte ratio is an effective marker of inflammation ana can have prognostic value in surgical patients. Aim: To evaluate the effect of an increased neutrophil/lymphocyte ratio (NLR) on perioperative complications ana overall ana disease-free survival in patients undergoing elective resection for stage II colon cancer. Material and Methods: Data was obtained from clinical charts, preoperative blood results and hospital records of all patients undergoing an elective curative resection for colon cancer, between 2000 and 2007. Preoperative NLR was calculated. Follow-up was obtained from a prospectively maintained colorectal cancer database, clinical records and questionnaires. Uni and multivariable analysis were performed to identify associations, and survival analysis was performed using Kaplan-Meier curves. Results: One hundred twenty two patients with a mean age of69years (52% males), were evaluated. Median follow-up was 73 months, and overall survival for 1 and 5years was 95% and 68%, respectively. On a multivariable analysis after adjusting for age, sex, tumor depth invasion, use of adjuvant therapies and American Society of Anesthesiology preoperative risk score, an NLR > 5 was associated with an increased perioperative complication rate (odds ratio: 3,06, p = 0,033). Kaplan-Meier survival analysis showed a worse overall and disease-free survival for patients with NLR greater than five. Conclusions: A preoperative NLR of five or more is associated with greater perioperative morbidity and worse oncological outcomes in patients undergoing resection for elective stage II colon cancer.
Subject(s)
Aged , Female , Humans , Male , Colonic Neoplasms/blood , Lymphocytes , Neutrophils , Colonic Neoplasms/mortality , Colonic Neoplasms/surgery , Disease-Free Survival , Follow-Up Studies , Kaplan-Meier Estimate , Leukocyte Count , Multivariate Analysis , Neoplasm Staging , PrognosisABSTRACT
The purpose of this study was to determine the association between human immunodeficiency virus (HIV) infection and tuberculosis (TB) among a cohort of heterosexual discordant couples (one partner HIV-positive and the other HIV-negative) enrolled at an HIV prevention and research centre in Lusaka, Zambia. All medical records identified from January 1994 to July 1998 were extensively reviewed. In addition, follow-up visits to local health department and chest clinics and to sputum analyses laboratories were conducted to validate the extracted medical data. The study used a nested approach based on a retrospective study design. The participants with HIV-associated tuberculosis (HAT), when compared with HIV-negative subjects with diagnosis of presumptive tuberculosis, were more likely to have presented with negative sputum analyses, to have been diagnosed with pulmonary tuberculous lesion, to have experienced relapse from tuberculosis, to have never been hospitalized for tuberculosis-related complications, and to have died due to tuberculosis. In addition, 9% of the urban heterosexual discordant couples enrolled in the primary cohort study were positive for presumptive tuberculosis. This study reports the first major impact of HIV infections on the outcomes of tuberculosis among heterosexual discordant couples. However, further research using vigorous methodological criteria is recommended to confirm the above findings.